Suboptimal Treatment of Anemia in CKD Non-Dialysis Patients: What Role Will HIF-PH Inhibitors Play?
Authors: Meghan Staudt, Tucker Hurtado, Jennifer Robinson BACKGROUND: The purpose of this study was to understand the real-world patient presentation and treatment priorities for CKD non-dialysis patients, focusing on the treatment of anemia of CKD. METHODS: Using a HIPAA-compliant, online chart audit tool, nephrologists (n=183) submitted de-identified clinical and non-clinical demographic information for 1,030 […]
New Drugs and Evolving Treatment Patterns in Lupus Nephritis: How Nephrologists and Rheumatologists Are Responding Differently to New Treatment Options
Authors: Ryan Rex, Tucker Hurtado, and Jennifer Robinson BACKGROUND: Early uptake and experience with recently approved lupus nephritis (LN) drugs belimumab and voclosporin reveal different perceptions, comfort levels, and prescribing intentions between nephrologists and rheumatologists. METHODS: Data were collected over four waves of research between February and May 2021 via online surveys with 50 […]
Comparing and Contrasting Glomerular Disease Patients: A Real World Analysis Showing Demographic, Clinical, and Treatment Differences Across More Than 1,000 Patients
Authors: Ryan Rex, Tucker Hurtado, and Jennifer Robinson BACKGROUND: One-half of nephrologists selected glomerular diseases as their leading area of interest in nephrology in 2020. These rare and often-idiopathic disorders are seen as particularly challenging to manage, but an influx of promising pipeline drugs may offer new treatment options in the not-so-distant future. METHODS: […]
SGLT2 Inhibitors: Will They Change the Face of Kidney Care?
Authors: Meghan Staudt, Tucker Hurtado, and Jennifer Robinson BACKGROUND: This research examines the evolving care and treatment of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), including the introduction and adoption of SGLT2 inhibitors. It includes trending on perceptions across specialists. METHODS: A total of 1,030 CKD non-dialysis patient records were […]
An Itch to Scratch: The Problem with Pruritus
Authors: Skylar Malone, Tucker Hurtado, and Jennifer Robinson BACKGROUND: Dialysis patients often suffer from some level of associated pruritus and nephrologists generally recognize the condition’s impact on patient lives, rating pruritus as a high unmet need for new therapeutic options. However, official diagnosis of CKD-associated pruritus and physician-reported estimates may be highly underestimated. METHODS: […]
Migraine Marketing Wars? AbbVie, Biohaven, Eli Lilly, Amgen Lead Push for Attention in Newly Competitive Space
From: Endpoints News By: Beth Snyder Bulik For a long time, migraine sufferers were stuck with the same old medicines and advice. Try some triptans, change your diet, maybe even see if a narcotic might help — but no major drug advances to prevent or stop debilitating migraine episodes in almost 30 years…(read more)
Buckle Up AbbVie, Amgen: Biohaven’s Oral CGRP Drug is Gaining Traction in Migraine, Doctors’ Survey Shows
From: FiercePharma By: Angus Liu With recent FDA approvals, the race for supremacy in migraine treatment is heating up among oral CGRP inhibitors, and a doctors’ survey is offering an early look at the winners. Piper Sandler conducted the survey with Spherix Global Insights a few weeks ahead of Qulipta’s FDA go-ahead in late […]
Spherix Global Insights Releases the Titles of Seven Abstracts To Be Presented at American Society of Nephrology Kidney Week 2021
Independently funded research on glomerular diseases, lupus nephritis, SGLT2 inhibitors, disparities in care, HIF-PH inhibitors, CKD-associated pruritus, and COVID-19 impacts showcased in Spherix abstracts and poster presentations EXTON, Pa., November 1, 2021 /PRNewswire/ — Spherix Global Insights, a leading market intelligence firm specializing in nephrology, is excited to announce the titles of seven abstracts that will […]
Spherix Global Insights Expands Expert Coverage of IgA Nephropathy Into EU Markets and Announces Upcoming Second Annual US Patient Audit
New research provides insight into unmet needs, current treatment paradigms, and nephrologists’ opinions on upcoming pipeline product potential across the UK, Germany, France, Italy, and Spain EXTON, Pa., October 28 , 2021 /PRNewswire/ — Spherix Global Insights, a leading market intelligence firm specializing in nephrology-based research and insights, announced this month the release of Market Dynamix™: IgA […]
Comparison of Therapy Selection Drivers Within the S1P Receptor Modulator and Fumarate Classes Among Multiple Sclerosis Patients Who Recently Switched Treatment
Author: Virginia R. Schobel, MSc BACKGROUND: The number of disease-modifying therapies (DMTs) within the S1P receptor modulator and fumarate classes has expanded with recent approvals of siponimod (BAF), ozanimod (RPC), and ponesimod in the S1P class and generic (Gx) dimethyl fumarate (DMF), diroximel fumarate (DRF), and monomethyl fumarate in the fumarate class. OBJECTIVE: To compare […]
